Roth Capital Issues Pessimistic Estimate for ALUR Earnings

Allurion Technologies Inc. (NYSE:ALUR) – Equities researchers at Roth Capital reduced their Q1 2025 earnings per share estimates for Allurion Technologies in a note issued to investors on Wednesday, March 26th. Roth Capital analyst J. Wittes now anticipates that the company will earn ($1.18) per share for the quarter, down from their previous forecast of ($0.92). The consensus estimate for Allurion Technologies’ current full-year earnings is ($9.96) per share. Roth Capital also issued estimates for Allurion Technologies’ Q2 2025 earnings at ($0.58) EPS, Q3 2025 earnings at ($0.67) EPS, FY2025 earnings at ($2.57) EPS and FY2026 earnings at ($0.53) EPS.

Allurion Technologies (NYSE:ALUR) last released its earnings results on Wednesday, March 26th. The company reported ($7.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($5.00) by ($2.00). The business had revenue of $5.59 million for the quarter, compared to the consensus estimate of $5.60 million.

A number of other brokerages have also weighed in on ALUR. Roth Mkm reissued a “buy” rating and set a $16.00 price target on shares of Allurion Technologies in a research note on Friday, March 21st. Chardan Capital reiterated a “neutral” rating and issued a $2.50 target price on shares of Allurion Technologies in a research note on Thursday, March 27th.

Allurion Technologies Stock Performance

Shares of ALUR opened at $3.33 on Monday. The company has a market capitalization of $15.94 million, a price-to-earnings ratio of -0.28 and a beta of -0.59. Allurion Technologies has a 1 year low of $2.15 and a 1 year high of $98.75. The company’s 50 day simple moving average is $4.03 and its 200 day simple moving average is $9.49.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Allurion Technologies stock. Geode Capital Management LLC lifted its holdings in Allurion Technologies Inc. (NYSE:ALUR) by 40.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 516,330 shares of the company’s stock after acquiring an additional 149,484 shares during the period. Geode Capital Management LLC owned approximately 0.80% of Allurion Technologies worth $317,000 as of its most recent SEC filing. Institutional investors and hedge funds own 21.39% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Shantanu Gaur acquired 8,000 shares of the business’s stock in a transaction dated Friday, March 28th. The shares were bought at an average cost of $3.35 per share, for a total transaction of $26,800.00. Following the acquisition, the chief executive officer now directly owns 8,000 shares in the company, valued at $26,800. This trade represents a ? increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 22.40% of the stock is currently owned by insiders.

About Allurion Technologies

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.